source
- FDA places partial hold on Bright Minds' seizure trial over mouse toxicity concernsThe FDA issued a partial clinical hold on Bright Minds Biosciences' planned phase 2 trial of BMB-101 in patients with developmental and epileptic encephalopathies. The hold was triggered by precli…
- AbbVie signs up to $757M deal with Beijing's Brise Pharma for two preclinical migraine candidatesAbbVie announced a discovery and commercialization agreement with Brise Pharma, a Beijing-based biotech company. The partnership covers two preclinical migraine programs and is valued at up to $75…